News
A Court That Decides Not to Decide
The European Court of Human Rights (ECtHR) is the continent's final arbiter on whether national laws violate fundamental human rights. It has ruled on everything from surveillance practices to prison conditions. But when it comes to cannabis prohibition, critics argue the court has consistently chosen to look the other way — and in doing so, may be undermining its own legal standards.
A detailed legal critique published in Opinio Juris, a leading international law forum, has put this pattern under a sharp lens. The argument is not simply that the ECtHR should legalise cannabis — it is something more procedurally pointed: that the court is failing to apply the same rigour it uses in other sensitive policy areas when evaluating whether cannabis laws infringe on rights protected under the European Convention on Human Rights (ECHR).
The Margin of Appreciation Problem
At the heart of the critique lies the court's use — and alleged overuse — of the "margin of appreciation" doctrine. This principle allows member states latitude to regulate sensitive social issues where there is no European consensus. On matters of drug policy, the ECtHR has repeatedly invoked this doctrine to decline meaningful review, deferring to national legislatures even when applicants argue their rights under Articles 8 (private life) or 14 (non-discrimination) of the ECHR have been violated.
The problem, legal scholars contend, is that the court does not apply this deference consistently. In areas such as LGBTQ+ rights, reproductive health, or religious expression, the ECtHR has been willing to scrutinise national laws closely, even in the absence of full European consensus. Cannabis prohibition, the argument goes, is being treated as a category apart — insulated from the kind of structured proportionality review that the court applies elsewhere.
"The court's reluctance to engage substantively with cannabis prohibition cases does not reflect a principled legal position — it reflects an institutional choice to treat drug policy as politically untouchable."
This is more than an academic concern. If the ECtHR is applying different standards of review based on the perceived political sensitivity of a topic, rather than the legal merits of the rights claim, that is a consistency problem that goes to the court's legitimacy.
What Rights Are Actually at Stake?
The rights arguments being advanced in cannabis cases before the ECtHR are not trivial. Applicants have raised Article 8 claims grounded in personal autonomy — the right to make decisions about one's own body and private conduct without state interference. Others have raised questions about proportionality: whether criminal penalties for personal cannabis use are a necessary and proportionate means of achieving a legitimate aim, particularly given the growing scientific literature on cannabis's comparatively modest harm profile relative to legal substances.
In a small number of decisions, the court has acknowledged these arguments exist. But it has stopped well short of engaging with them analytically, typically dismissing applications as inadmissible or ruling in favour of state discretion without conducting a full proportionality assessment. Critics argue this approach effectively renders the Convention silent on an issue affecting millions of Europeans.
Europe Is Moving — Is the Court Keeping Pace?
The legal landscape across Europe has shifted considerably in recent years. Germany's partial legalisation came into force in 2024. Luxembourg, the Netherlands, and Switzerland have moved toward regulated frameworks. Malta, which introduced the most comprehensive personal-use reform in the EU in 2021 through its Cannabis Reform Act, created a model that explicitly tried to reframe cannabis not as a criminal matter but as a public health and autonomy issue.
That Maltese framing — anchored in harm reduction principles and the recognition that criminalisation causes its own harms — aligns closely with the rights arguments being made before the ECtHR. ARUC, Malta's regulatory authority for cannabis, and organisations such as the Cannabis Harm Reduction Association (CHRA) have built their operational frameworks around the premise that individuals have a right to be protected from the harms of both cannabis and its prohibition. It is precisely this logic that the ECtHR has so far declined to engage.
If the court continues to defer to national governments regardless of how the regulatory landscape evolves, it risks becoming a lagging indicator rather than a living instrument — the very standard it has historically claimed to uphold.
Why It Matters Beyond the Courtroom
The ECtHR does not set drug policy directly. But its rulings shape the legal environment in which national reforms are debated and defended. A court that refuses to scrutinise prohibition provides implicit cover for member states that resist reform, and weakens the legal arguments of those — patients, harm reduction advocates, civil society organisations — who argue that current laws are not merely bad policy, but rights violations.
The question Opinio Juris is raising is not whether cannabis should be legal. It is whether Europe's human rights court is doing its job. On the evidence so far, that remains an open and uncomfortable question.
Sources
Opinio Juris
Featured image: Photo by Artur Roman on Pexels
Members Discussion